Regulatory approval

Published by the European Medicines Agency. Approved

The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.

This is written in the approval document as:

Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.

Citation

Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
EMA (1)	v::RET	Any solid tumor	Selpercatinib

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2024-04-29	European Medicines Agency	Indication received approval from the European Commission.